JNJ-64007957 is a bispecific antibody that targets BCMA, which is expressed in mature B lymphocytes, and CD3, which is expressed on T-cells, was created under a collaboration between Genmab and Janssen using Genmab's DuoBody technology. JNJ-64007957 is being investigated in a Phase I clinical study to treat relapsed or refractory multiple myeloma.

Back to top

Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells.1 Multiple myeloma is the third most common blood cancer in the U.S., after leukemia and lymphoma.2 Approximately 26,850 new patients will be diagnosed with multiple myeloma and approximately 11,240 people will die from the disease in the U.S. in 2015.3 Globally, it is estimated that 124,225 people will be diagnosed and 87,084 will die from the disease in 2015.4  While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms which can include bone problems, low blood counts, calcium elevation, kidney problems or infections.5 Patients who relapse after treatment with standard therapies, including PIs or IMiDs, have poor prognoses and few treatment options.6

JNJ-64007957 is being investigated in a Phase I study in relapsed or refractory multiple myeloma. For more information, visit

1 American Cancer Society. "Multiple Myeloma Overview." Available
at Accessed August 2015.

2 National Cancer Institute. "A Snapshot of Myeloma." Available at Accessed September 2015.

3 American Cancer Society. "What are the key statistics about multiple myeloma?" Accessed September 2015.

4  GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide: Number of New Cancers in 2015. Available at: Accessed September 2015.

5  American Cancer Society. "How is Multiple Myeloma Diagnosed?" Accessed August 2015.

6 Janssen JH, et al. Blood. 2012; 120.2974.


Back to top